TL;DR: Aetna, a CVS Health company, modified CPB 0495 governing hematopoietic cell transplantation for Hodgkin's disease, effective December 11, 2025. Here's what billing teams need to do.
This update to the Aetna hematopoietic cell transplantation coverage policy affects how you document and bill autologous and allogeneic transplants for Hodgkin's disease (HD) under CPT codes 38240 and 38241, among others. The policy sets specific medical necessity criteria that determine whether claims for harvesting (CPT 38205, 38206), bone marrow procurement (CPT 38230, 38232), transplant preparation (CPT 38210–38213), and HLA typing (CPT 86813, 86817, 86821) will be covered. If your transplant program bills Aetna for HD cases, review your documentation against CPB 0495 Aetna criteria before submitting claims dated on or after the effective date of December 11, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Hematopoietic Cell Transplantation for Hodgkin's Disease |
| Policy Code | CPB 0495 |
| Change Type | Modified |
| Effective Date | December 11, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology/Oncology, Bone Marrow Transplant Programs, Radiation Oncology, Hematopathology |
| Key Action | Confirm transplanting institution selection criteria are documented in the medical record before billing CPT 38240 or 38241 for any HD case |
Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025
The Aetna hematopoietic cell transplantation coverage policy under CPB 0495 takes a two-track approach to medical necessity. Track one: the transplanting institution has its own formal patient selection criteria. Track two: Aetna's own criteria apply when the institution doesn't have them.
This matters for your billing team because the documentation required differs depending on which track applies.
Autologous Transplantation (CPT 38241, 38206, 38232)
Aetna covers autologous hematopoietic cell transplantation for Hodgkin's disease when the member meets the transplanting institution's selection criteria. Full stop — if your institution has documented selection criteria and the patient qualifies, that's your primary path to coverage.
When the institution has no formal criteria, Aetna's own two-part test applies. The member must be in primary induction failure or beyond first remission. And the member must have no serious organ dysfunction, based on the transplanting institution's evaluation. Both conditions are required — not one or the other.
For billing purposes, this means your prior authorization submission and medical record need to explicitly address these two criteria when institutional criteria aren't in play. A vague note saying "patient failed first-line therapy" won't cut it. Document the specific remission status and organ function evaluation.
Allogeneic Transplantation (CPT 38240, 38205, 38230)
The allogeneic pathway covers a broader set of clinical scenarios. Aetna covers allogeneic transplantation for relapsed HD, persistent HD after a prior autologous transplant, and primary refractory HD — provided the member meets the transplanting institution's selection criteria.
Again, when institutional criteria are absent, both prongs of the medical necessity test must be met: primary induction failure or beyond first remission, plus no serious organ dysfunction.
Non-myeloablative allogeneic transplantation — sometimes called a "mini-transplant" or reduced intensity conditioning (RIC) transplant — gets its own specific coverage path. Aetna covers this for members with relapsed or primary refractory HD, including post-autologous failures, when the member is eligible for conventional allografting. Eligibility for conventional allografting is the determining factor here. If that's not clearly documented, expect a claim denial.
Prior authorization for allogeneic transplants is standard practice with Aetna on high-cost oncology procedures. Don't submit claims for CPT 38240 without confirming your PA is in place and specifically addresses the clinical scenario — relapsed, refractory, or post-autologous.
HLA Typing and Donor Search (CPT 38204, 86813, 86817, 86821)
Aetna considers HLA typing and donor management covered when the selection criteria are met. CPT 86813 (HLA typing, A, B or C, multiple antigens), CPT 86817 (DR/DQ, multiple antigens), and CPT 86821 (lymphocyte culture, mixed) are all in the covered group under this coverage policy.
CPT 38204 (management of recipient hematopoietic progenitor cell donor search and cell acquisition) is also covered when criteria are met. Allogeneic cases require donor sourcing — make sure this code is in your charge capture workflow for allo cases.
Transplant Preparation Codes (CPT 38210–38213)
Preparation procedures are covered when selection criteria are satisfied. This includes CPT 38210 (specific cell depletion with harvest, T-cell), 38211 (tumor cell depletion), 38212 (red blood cell removal), and 38213 (platelet depletion). Bill the specific preparation code that reflects what was actually performed — don't default to an unspecified code when a more specific one applies.
Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications
There's one clear experimental designation in this policy, and it's a significant one for some transplant programs.
Tandem transplants — also called sequential transplants — are considered experimental, investigational, or unproven for Hodgkin's disease. Aetna's position is that the evidence doesn't support their effectiveness and safety for this indication. Don't submit claims for tandem transplant sequences in HD cases expecting coverage. You'll face denial.
This mirrors a broader pattern across payers: combination or sequential transplant strategies in hematologic malignancies are under scrutiny. The evidence bar for tandem approaches hasn't been cleared to Aetna's standard, at least not for HD.
If your program is considering a tandem protocol for an HD patient on an Aetna plan, loop in your compliance officer and billing consultant before scheduling — not after. The prior authorization process will make Aetna's position clear, but getting that answer before clinical planning begins saves everyone time.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Autologous HCT — patient meets institutional selection criteria | Covered | CPT 38241, 38206, 38232 | Institutional criteria must be documented |
| Autologous HCT — primary induction failure or beyond 1st remission, no serious organ dysfunction | Covered | CPT 38241, 38206, 38232 | Both criteria required; applies when no institutional criteria exist |
| Allogeneic HCT — relapsed HD, meeting institutional selection criteria | Covered | CPT 38240, 38205, 38230 | Includes post-autologous relapse or persistent disease |
| Allogeneic HCT — primary refractory HD, meeting institutional selection criteria | Covered | CPT 38240, 38205, 38230 | Prior auth required |
| Allogeneic HCT — primary induction failure or beyond 1st remission, no serious organ dysfunction | Covered | CPT 38240, 38205, 38230 | Fallback criteria when institutional criteria absent |
| Non-myeloablative allogeneic HCT ("mini-transplant" / RIC) — relapsed or refractory HD | Covered | CPT 38240, 38205 | Must be eligible for conventional allografting |
| HLA typing and donor search | Covered (criteria-dependent) | CPT 38204, 86813, 86817, 86821 | Covered when selection criteria are met |
| Transplant preparation (T-cell depletion, tumor cell depletion, RBC/platelet removal) | Covered (criteria-dependent) | CPT 38210, 38211, 38212, 38213 | Bill the specific preparation code performed |
| Tandem (sequential) transplants for HD | Experimental / Not Covered | — | Insufficient evidence for effectiveness and safety |
Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your documentation templates against CPB 0495 before December 11, 2025. Every HD transplant case needs explicit documentation of either institutional selection criteria or both Aetna fallback criteria. The organ dysfunction evaluation is a common gap — make sure the transplanting institution's assessment is in the record, not just implied by the plan of care. |
| 2 | Confirm prior authorization is in place for all allogeneic transplant cases. CPT 38240 without PA on an Aetna plan is a fast path to denial. Your PA request should specify the clinical scenario — relapsed, refractory, or post-autologous — because each has a different coverage path under this policy. |
| 3 | Flag any tandem transplant cases on Aetna plans immediately. If you have HD patients on Aetna who are being considered for sequential transplant protocols, escalate to your compliance officer now. Billing for tandem transplants will result in denial, and retroactive appeals on experimental designations are difficult. |
| 4 | Update your charge capture to include CPT 38204 on all allogeneic cases. Donor search and cell acquisition management often gets missed in charge capture workflows. If you're billing CPT 38240, CPT 38204 should be in your standard order set. |
| 5 | Add HLA typing codes (CPT 86813, 86817, 86821) to your covered code list for HD cases meeting criteria. These are explicitly covered under CPB 0495. If your team has been leaving these off for Aetna cases out of habit or uncertainty, that's lost reimbursement. Verify they're in your charge master for transplant cases. |
| 6 | Distinguish RIC/mini-transplant cases clearly in documentation. For non-myeloablative allogeneic transplants, Aetna requires evidence that the patient is eligible for conventional allografting. That eligibility determination needs to appear explicitly in the medical record — not just the decision to proceed with RIC. Without it, the claim reads as an unsupported intensity choice rather than a covered clinical decision. |
| 7 | Verify that chemotherapy and radiation billing codes (CPT 96401 series, 77261–77295) are correctly linked to the transplant episode. These codes appear in the related-codes list for CPB 0495. While they aren't transplant codes themselves, they're part of the conditioning and supportive care picture. Confirm your billing team understands which services fall under the transplant episode versus standard oncology billing. |
If your program handles a high volume of Aetna HD cases, have your compliance officer review your current PA workflow against the updated criteria in CPB 0495 before the effective date. The two-track selection criteria framework — institutional criteria versus Aetna's fallback — creates real documentation variability across cases. Your team needs a consistent process for identifying which track applies.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0495
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 38204 | CPT | Management of recipient hematopoietic progenitor cell donor search and cell acquisition |
| 38205 | CPT | Blood-derived hematopoietic progenitor cell harvesting for transplantation — allogeneic |
| 38206 | CPT | Blood-derived hematopoietic progenitor cell harvesting for transplantation — autologous |
| 38210 | CPT | Transplant preparation of hematopoietic progenitor cells; specific cell depletion with harvest, T-cell |
| 38211 | CPT | Transplant preparation — tumor cell depletion |
| 38212 | CPT | Transplant preparation — red blood cell removal |
| 38213 | CPT | Transplant preparation — platelet depletion |
| 38230 | CPT | Bone marrow harvesting for transplantation — allogeneic |
| 38232 | CPT | Bone marrow harvesting for transplantation — autologous |
| 38240 | CPT | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor |
| 38241 | CPT | Hematopoietic progenitor cell (HPC); autologous transplantation |
| 86813 | CPT | HLA typing; A, B or C multiple antigens |
| 86817 | CPT | HLA typing; DR/DQ, multiple antigens |
| 86821 | CPT | HLA typing; lymphocyte culture, mixed (MLC) |
Get the Full Picture for CPT 38205
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.